Trafalgar International, Inc. has taken a significant step in its corporate governance by filing a definitive information statement to approve its Amended and Restated Articles of Incorporation. This move, filed on November 5, 2026, is crucial as it outlines major changes to the company’s capital structure and governance framework.

The restructuring of Trafalgar's Articles is designed to simplify its corporate charter and remove outdated provisions related to preferred stock conversion. These changes aim to provide greater clarity regarding the rights of shareholders and the company’s authorized capital structure.

Background

Trafalgar International, Inc., classified under the SIC code 2834 for Pharmaceutical Preparations, operates as a smaller reporting company on the OTC exchange under the ticker TRFA. The company has undergone various transformations, previously known as Greater Cannabis Company, Inc. before its name change in January 2017. The recent filings indicate a focus on restructuring to enhance its market position.

What the Filing Says

The definitive information statement reveals that the Board of Directors approved the Restated Articles on October 12, 2026, and secured written consent from Trafalgar Asset Management, LLC, the holder of all outstanding Series A and Series B Preferred Stock. The filing states, “No shareholder meeting will be held, and no proxies are being solicited.”

The Restated Articles authorize 2 billion shares of common stock and 20 million shares of preferred stock, with significant changes to the Series A and Series B Preferred Stock designations. Notably, all conversion rights associated with Series A and Series B will be eliminated, and Series A will lose its general voting rights.

Impact

This restructuring is set to affect various stakeholders, including shareholders and potential investors. By simplifying its capital structure, Trafalgar aims to reduce the complexity that may deter investment and improve its public-market capitalization. The changes may also influence how other companies in the pharmaceutical preparations sector approach their governance structures.

What's Next

The filing does not say what happens next, but it indicates that Trafalgar will not implement the Restated Articles until all requisite approvals and applicable federal notice and waiting requirements have been satisfied. This suggests that stakeholders will need to remain attentive to future filings and announcements regarding the implementation of these changes.